BSEM

$BSEM Q2 '26 Earnings Results & Recap BioStem Technologies reported Q2 2026 net revenue of $7.9M, a 28% YoY decrease, driven by CMS reimbursement changes that reduced physician office revenue by 90% compared to Q2 2025.

$BSEM 's latest squeeze play

$BSEM Earnings release and 10Q should be interesting to see how the business is operating now that they are play by the rules everyone else is. Also, the 10Q will offer investors a lot more information than they reported as a pink sheet company.

I honestly dont understand the valuation gap between these two RMTG has a better balance sheet better margins better growth and better profits $BSEM is trailing in every category but still trades at a premium it seems like the market hasnt looked at the actual numbers for RMTG yet

What really stands out to me is the equity position of both companies RMTG has positive shareholders equity which means they have a buffer against any downturns $BSEM has a deficit which means they are technically insolvent on paper that is a massive differance in risk profile for anyone looking at the balance sheets

The peptide and stem cell industry is booming right now and RMTG is capitalizing on that growth with real revenue and real earnings $BSEM is present in the sector but they arent converting that market opportunity into profits yet the difference in execution is obvious when you compare the quarterly filings

$BSEM has a lot of hype around it but the financial statements tell a different story they are losing money and diluting shareholders to stay alive RMTG is quietly building a profitable business with a tiny market cap and no dilution the fundamentals favor RMTG in almost every category

I ran the numbers on both companies and the price to sales ratio for RMTG is incredibly low compared to $BSEM if RMTG traded at the same multiple as BSEM their share price would be significantly higher its just basic arithmetic based on the revenues they are reporting and the revenue gap is widening every quarter

When you strip away all the hype and just look at the hard numbers RMTG is the stronger play on paper they have positive equity they have growing revenue and they have net income $BSEM has high debt loads negative equity and recurring losses the fundamentals just arent comparable

Ive been following the stem cell and peptide sector for a while and its clear that RMTG is one of the few microcaps actually hitting their targets they are growing rapidly and they are doing it with a clean balance sheet $BSEM is hanging on by a thread with debt and dilution and their growth rate is nowhere near what RMTG is showing

The first quarter results really highlight the difference between the two RMTG showed rapid revenue growth and a profitable bottom line $BSEM posted another quarter of red ink and stagnant sales if you compare the income statements directly one company is executing and the other is just hoping for a turnaround

If you look at the share structures side by side its pretty alarming $BSEM has a history of diluting shares to stay afloat which hurts everyone holding the stock RMTG has a stable float and they arent reliant on secondary offerings because their business is already self funding that is a huge advantage for RMTG holders going forward